Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Co-Diagnostics, Inc. Common Stock

CODX

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Last trade $0.1935
Day change -$0.0314 (-13.96%)
Day range $0.175 – $0.222
Volume 861,149
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.31M
Price / earnings
—
Price / book
0.25×
Price / sales
2.69×
EV / sales
1.86×
EV / EBITDA
-0.06×

Profitability

Earnings per share
-$4.52
Return on assets
-371.14%
Return on equity
-503.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.77×
Quick ratio
0.5×
Cash ratio
0.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.19M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CODX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$282.88K$166.13K$145.95K$263.92K$145.38K$162.91K$50.28K$149.33K
Cost of revenue$303.34K$45.3K$193.77K$142.4K$26.29K$32.11K$21.59K$255.07K
Gross profit-$20.46K$120.83K-$47.81K$121.53K$119.1K$130.8K$28.69K-$105.74K
Selling, general and administrative$2.45M$1.97M$2.97M$2.41M$2.38M$3.21M$3.43M$6.64M
Research and development$3.57M$4.15M$5.93M$5.1M$4.48M$4.69M$4.87M$4.81M
Total operating expenses$6.25M$6.32M$9.16M$26.66M$7.13M$8.19M$8.58M$11.8M
Operating income-$6.27M-$6.2M-$9.21M-$26.54M-$7.01M-$8.06M-$8.55M-$11.91M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.31M-$6.26M-$9.14M-$26.22M-$7.05M-$7.72M-$7.52M-$11.04M
Income taxes$500$19.17K$520-$473.72K-$1.17M$12.33K$12K-$8.18K
Net income-$6.31M-$6.28M-$9.14M-$25.75M-$5.89M-$7.73M-$7.53M-$11.03M
Net income attributable to common shareholders-$6.31M-$6.28M-$9.14M-$25.75M-$5.89M-$7.73M-$7.53M-$11.03M
EBITDA-$6.05M-$6M-$8.95M-$7.39M-$6.75M-$7.77M-$8.27M-$11.55M
Basic earnings per share-$1.01-$1.46-$4.06-$13.65-$4.66-$7.00-$7.05-$10.72
Diluted earnings per share-$1.01-$1.46-$4.06-$13.65-$4.66-$7.00-$7.05-$10.72

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Investing.com

Is Co-Diagnostics National Security’s Next Diagnostic Pick?

Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.

Benzinga

Co-Diagnostics Reports Full Year 2025 Financial Results

Co-Diagnostics (NASDAQ: CODX) reported full year 2025 results with revenue of $0.6 million versus $3.9 million in 2024, primarily due to lower grant revenue. The company posted a net loss of $46.9 million ($35.25 per share) compared to $37.6 million in 2024, driven by an $18.9 million non-cash impairment charge on intangible assets. Cash reserves declined to $11.9 million from $29.7 million. However, the company advanced its global commercialization strategy through CoSara and CoMira joint ventures, progressed clinical pipeline programs, and expanded AI capabilities.

Benzinga

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization

Co-Diagnostics (NASDAQ: CODX) has shipped PCR Pro instruments and TB test kits to its joint venture CoSara Diagnostics in India to begin clinical performance studies. The company's PCR platform and TB test design align with new WHO recommendations for near-point-of-care molecular testing using tongue swab samples, positioning Co-Dx favorably for regulatory submissions in India.

Benzinga

Co-Diagnostics Announces Reverse Stock Split

Co-Diagnostics Inc. (NASDAQ: CODX) announced a 1-for-30 reverse stock split effective January 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and the stock will continue trading under the symbol 'CODX' on a split-adjusted basis.

Benzinga

Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India

Co-Diagnostics' joint venture CoSara will participate in VIROCON 2025, presenting ongoing preclinical studies for tuberculosis and HPV tests on their PCR point-of-care platform, with promising early results supporting advancement to clinical performance testing.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 2, 20261-for-30reverse split